Market Outlook:-
Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men. The average age of a prostate cancer diagnosis is 66 years.
However, one-time screening and early diagnosis are likely to increase the success rate of treatment.
The global Prostate Cancer market is anticipated to reach a value of USD 18 billion by 2026.
Market Dynamics:-
• Increasing disease prevalence will act as the primary driver for market growth.
• Around 200,000 men are diagnosed with it every year, and most of them are over the age of 50. It is estimated that nearly 30,000 men died because of prostate cancer in 2018.
• Other market drivers include rapid advancement in oncology screening and diagnostics as well as innovations in drug development.
• However, the high cost associated with diagnostic tests and adverse effects of treatment will affect market growth.
• An increasing trend is to bring effective immune-based cancer treatments to patients with prostate cancer.
• Immunotherapy is a promising new treatment currently being developed in research. Provence, also known as sipuleucel-T is the only FDA-approved immunotherapy for prostate cancer.
Market Segmentation:-
• The Global Prostate Cancer market report segments the market by therapy, by end-user, and by region.
• Based on therapy, the market is segmented into hormonal treatment; chemotherapy; immunotherapy; radiation and focal therapies.
• Based on the end-user, the global Prostate Cancer market has been segmented into hospitals, ambulatory surgical centers, and specialty clinics.The hospital end-user type segment is expected to account for the highest share.
Download free report sample @ https://www.datamintelligence.com/download-sample/prostate-cancer-market
Geographical Trends:-
By geography, the global market is segmented into North America, Asia-Pacific (APAC), Europe, South America, and the Middle East and Africa (MEA).
North America is the leading global market with the largest revenue share in 2017 owing to the high prevalence of the disease in the US. Next to skin cancer, prostate cancer is the most common cancer in American men. As per the American Cancer Society’s, about 164,690 new cases of prostate cancer will be diagnosed in 2018. Hence, this region witnesses high investment in R&D for the development of newer immunotherapies.
Competitive Landscape:-
Major Players:
• Johnson & Johnson
• Astella, Inc.
• Sanofi Aventis
• IPSEN
• Bayer AG
• AstraZeneca
• Valent Pharmaceuticals LLC
View full report sample @ https://www.datamintelligence.com/research-report/prostate-cancer-market
For any inquiry about the report@ https://www.datamintelligence.com/enquiry/prostate-cancer-market
About Us:
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions. We monitor and analyze the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products.
For more information:
Sai Kiran
Sales Manager
Website: www.datamintelligence.com
Email:
[email protected]